12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-FGFR4Rx: Phase I started

Isis began a Phase I trial to evaluate ISIS-FGFR4Rx.

Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad,...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >